Answers are grounded in this paper and cite their sources.
Ginseng, as a traditional medicinal and edible resource, has shown potential in the treatment of neurodegenerative diseases, particularly Parkinson’s disease (PD), through its active components, ginsenosides (GS) and ginsenoside Re (GsRe). This study aimed to systematically investigate the neuroprotective effects and molecular underpinnings of total ginsenosides (GS) and ginsenoside Re (GsRe) in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced PD mouse model, with a focus on gut-brain axis modulation. The results showed that GS and GsRe ameliorated motor deficits, reduced substantia nigra pars compacta (SNpc) dopaminergic neuron loss, restored intestinal barrier integrity, and reversed gut dysbiosis. Mechanistically, GsRe crossed the BBB (Blood brain Barrier), upregulated brainderived neurotrophic factor (BDNF), and inhibited the TLR4 adaptor WDFY1, blocking excessive NFκB activation, M1 microglial polarization, and neuronal apoptosis. BDNF deficiency exacerbated TLR4 pathway hyperactivation, suggesting that BDNF modulates TLR4mediated neuroinflammation and contributes to the neuroprotective effects of GsRe. GS and GsRe target the gutbrain axis as an integrated hub: normalizing gut microecology to limit peripheral inflammatory signal translocation, while suppressing central neuroinflammation via the BDNF/TLR4 axis. These findings reveal a gut microbiota/gut brain axis whereby GsRe alleviates neuroinflammation by concurrently modulating gut microbiota composition and the BDNF/TLR4 pathway, providing a mechanistic basis for GS/GsRe based PD interventions.
No takes yet. Share an insight, caveat, or question.
Tang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: